布地奈德联合异丙托溴胺治疗慢性阻塞性肺疾病的临床疗效观察  

Clinical Efficacy of Budesonide Combined with Iipratropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease

作　　者：郭蕊蕊 李丹[1] 陈展鹏 刘凯[3] GUO Rui-rui;LI Dan;CHEN Zhan-peng;LIU Kai(Department of Respiratory and Critical Care Medicine,Zhengzhou Central Hospital,Zhengzhou 450007,China;Department of Rehabilitation Medicine,Zhengzhou Central Hospital,Zhengzhou 450007,China;Department of Endocrinology,Zhengzhou Central Hospital,Zhengzhou 450007,China)

机构地区：[1]郑州市中心医院呼吸与危重症医学科,郑州450007 [2]郑州市中心医院康复医学科,郑州450007 [3]郑州市中心医院内分泌科,郑州450007

出　　处：《四川解剖学杂志》2023年第2期106-108,共3页Sichuan Journal of Anatomy

摘　　要：目的:探讨布地奈德联合异丙托溴胺治疗慢性阻塞性肺疾病(COPD)的临床疗效.方法:选取2019年12月至2022年5月本院收治的134例COPD患者作为研究对象.根据治疗方式不同将其分为观察组(n=68,采用布地奈德和异丙托溴胺治疗)和对照组(n=66,采用布地奈德治疗).比较两组患者气道重塑相关指标、氧化应激指标、肺功能改善情况及不良反应发生率.结果:治疗后观察组血清基质金属蛋白酶(MMP)-9、白细胞介素(IL)-8水平均低于对照组,差异有统计学意义(P<0.05).治疗后观察组丙二醛(MDA)水平均低于对照组,超氧化物歧化酶(SOD)、和谷胱甘肽过氧化物酶(GPX)水平均高于对照组,差异有统计学意义(P<0.05).治疗后观察组1秒用力肺活量(FEV1)、用力肺活量(FVC)、FEV1/FVC值均高于对照组,差异有统计学意义(P<0.05).观察组与对照组不良反应发生率比较,差异无统计学意义(P>0.05).结论:布地奈德联合异丙托溴胺可有效抑制COPD患者氧化应激,减少气道重塑的发生,进而改善肺部功能,临床疗效更佳.Objective:To analyze the clinical efficacy of budesonide combined with ipratropium bromide in the treatment of chronic obstructive pulmonary disease(COPD).Methods:A total of 134 COPD patients admitted to our hospital from December 2019 to May 2022 were selected in this study.According to different treatment methods,they were divided into the observation group(n=68,treated by budesonide and Ipratropium bromide)and the control group(n=66,treated by budesonide).The airway remodeling related indicators,oxidative stress indicators,improvement of lung function,and incidence of adverse reactions were compared between two groups.Results:After treatment,the levels of serum matrix metallopeptidase(MMP)-9 and interleukin(IL)-8 in the observation group were lower than those in the control group(P<0.05),the levels of serum malonaldehyde(MDA)in the observation group were lower than those in the control group,and the levels of superoxide dismutase(SOD)and glutathione peroxidase(GPX)in the observation group were higher than those in the control group(P<0.05).After treatment,the values of forced expiratory volume in the first second(FEV1),forced vital capacity(FVC)and FEV1/FVC in the observation group were higher than those in the control group(P<0.05).The incidence of adverse reactions between the two groups were not statistically significant(P>0.05).Conclusion:Budesonide combined with ipratropium bromide can effectively inhibit oxidative stress in patients with COPD,reduce the occurrence of airway remodeling,and improve lung function,which has better clinical efficacy.

关 键 词：慢性阻塞性肺疾病 布地奈德 异丙托溴胺 气道重塑 氧化应激 

分 类 号：R563.9[医药卫生—呼吸系统]